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Targeted mitochondrial therapy 
using MitoQ shows equivalent 
renoprotection to angiotensin 
converting enzyme inhibition but 
no combined synergy in diabetes
Micheal S. Ward1, Nicole B. Flemming1,2, Linda A. Gallo  1,2, Amelia K. Fotheringham1,2, 
Domenica A. McCarthy1, Aowen Zhuang1,3, Peter H. Tang6, Danielle J. Borg1,2, Hannah 
Shaw1, Benjamin Harvie7, David R. Briskey4, Llion A. Roberts  4, Manuel R. Plan8, Michael P. 
Murphy9, Mark P. Hodson  3,5,8 & Josephine M. Forbes  1,3,10
Mitochondrial dysfunction is a pathological mediator of diabetic kidney disease (DKD). Our objective 
was to test the mitochondrially targeted agent, MitoQ, alone and in combination with first line 
therapy for DKD. Intervention therapies (i) vehicle (D); (ii) MitoQ (DMitoQ;0.6 mg/kg/day); (iii) Ramipril 
(DRam;3 mg/kg/day) or (iv) combination (DCoAd) were administered to male diabetic db/db mice for 12 
weeks (n = 11–13/group). Non-diabetic (C) db/m mice were followed concurrently. No therapy altered 
glycaemic control or body weight. By the study end, both monotherapies improved renal function, 
decreasing glomerular hyperfiltration and albuminuria. All therapies prevented tubulointerstitial 
collagen deposition, but glomerular mesangial expansion was unaffected. Renal cortical concentrations 
of ATP, ADP, AMP, cAMP, creatinine phosphate and ATP:AMP ratio were increased by diabetes and 
mostly decreased with therapy. A higher creatine phosphate:ATP ratio in diabetic kidney cortices, 
suggested a decrease in ATP consumption. Diabetes elevated glucose 6-phosphate, fructose 
6-phosphate and oxidised (NAD+ and NADP+) and reduced (NADH) nicotinamide dinucleotides, which 
therapy decreased generally. Diabetes increased mitochondrial oxygen consumption (OCR) at complex 
II-IV. MitoQ further increased OCR but decreased ATP, suggesting mitochondrial uncoupling as its 
mechanism of action. MitoQ showed renoprotection equivalent to ramipril but no synergistic benefits of 
combining these agents were shown.
There is a rising global incidence of diabetes where progressive diabetic kidney disease (DKD) seen in 25–40% 
of individuals, is a major factor driving mortality risk1. Inhibitors of the renin-angiotensin system are first line 
therapies administered upon clinical presentation of DKD2. Although recent figures suggest a stabilisation in 
the prevalence of DKD3, current therapies only slow progression of the disease and transplantation or dialysis is 
ultimately required.
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With diabetes, it is postulated that tissues with greater metabolic demand are at risk of chronic complica-
tions4,5. The kidney cortex has high requirements for aerobic adenosine triphosphate (ATP) synthesis via oxida-
tive phosphorylation6, due to processes such as tubular reabsorption of glucose, ions and other metabolites from 
the urinary filtrate by tubules7,8, and control of glomerular filtration9. As such, the kidneys contain many mito-
chondria10 and at rest are second only to the heart in oxygen consumption when considered by organ weight6. In 
diabetes, metabolism11,12, oxygen consumption13–15 and glomerular ATP concentrations9 are increased early in 
disease pathogenesis.
Mitochondrial dysfunction is seen early in the development of experimental DKD13,16 and has been identified 
as a major contributor to disease progression both in preclinical models13,17,18 and in humans with DKD19–21. 
There is also evidence of mitochondrial dysfunction in other chronic kidney diseases22–24. Further, mitochondrial 
dysfunction can confer susceptibility to chronic kidney disease (CKD)24–26. Therapies thought to improve mito-
chondrial function, including Coenzyme Q10 (CoQ10)18,27,28 and SS-31 have beneficial effects on kidney function 
and fibrosis in experimental models of diabetes29 and obesity30.
MitoQ is a form of coenzyme Q with a lipophilic cation that selectively facilitates its uptake into the mito-
chondria where it is postulated to act as an anti-oxidant. MitoQ has demonstrated consistent benefits in disease 
settings31,32 and is under investigation in CKD Stages 3–5 (NCT02364648). To date, only one study has explored 
the utility of MitoQ in treating DKD, where daily administration prevented albuminuria in an experimental 
model of monogenic diabetes of the young (MODY), the Ins2Akita mouse17.
Therefore, in the present study, our objective was to compare the renoprotection afforded by MitoQ as a 
monotherapy and in combination with a first line therapy for DKD, the angiotensin-converting enzyme (ACE) 
inhibitor, ramipril. The ways in which MitoQ and ramipril differed in conferring renoprotection in the diabetic 
kidney were also investigated.
Results
Body mass and metabolic parameters. At study commencement, all diabetic mice were overweight, 
with elevated fasting plasma glucose and glycated hemoglobin concentrations, when compared with non-diabetic 
mice (Table 1). By the study end, fasting plasma glucose (Fig. 1A) insulin (Fig. 1B), and glycated hemoglobin 
concentrations (Fig. 1C) were all markedly increased by diabetes, but not affected by therapy. However, ramipril 
treated mice had lower glycated hemoglobin concentrations when compared with MitoQ monotherapy (Fig. 1C). 
All diabetic mice had glucose intolerance, determined by an oral glucose tolerance test (OGTT), which was not 
altered by therapy (Fig. 1D,E). All diabetic mice remained overweight at the study end and this was not differ-
ent among groups (Fig. 1F). Mice with diabetes consumed more food and water and had greater urine output 
throughout the study and these were unaffected by therapy (Table 1).
Renal function and structure. Diabetic mice had significant albuminuria, shown by elevations in 24 h 
urinary albumin excretion rate (AER; Fig. 2A) and urinary albumin creatinine ratio (ACR; Fig. 2B) both early 
(week 4) and later (week 9) during the development of DKD. Early in disease, MitoQ, ramipril and their combi-
nation attenuated albuminuria assessed by AER, but not ACR in diabetic mice (Fig. 2A,B, left). Later in disease 
development, MitoQ attenuated the diabetes-induced increases in AER, but this was not seen with ramipril or 
combination therapy (Fig. 2A, right). However, both MitoQ or ramipril monotherapy modestly decreased the 
diabetes-induced increases in ACR later in DKD (Fig. 2B, right).
By the study end, diabetic mice which did not receive therapy had a ~two-fold increase in GFR compared with 
non-diabetic mice (Fig. 2C, left). This was supported by a decrease in plasma cystatin C with diabetes (Fig. 2C, 
right). The diabetes-induced increase in GFR was ameliorated by all therapies (Fig. 2C, left). However, plasma 
cystatin C concentrations in diabetic mice were only increased by MitoQ monotherapy (Fig. 2C, right).
Control Diabetes DMitoQ DRam DCoAd
At study commencement
Body wt (g) 25.4 ± 1.5 39.1 ± 1.4* 37.2 ± 2.5* 36.2 ± 2.5* 40.0 ± 1.8*
FBG (mmol/L) 9.1 ± 2.6 23.8 ± 4.8* 29.3 ± 7.0* 22.2 ± 4.1* 24.5 ± 4.5*
GHb (%) 5.7 ± 1.9 7.8 ± 2.5* 7.4 ± 1.6* 6.7 ± 2.9* 7.0 ± 1.9*
At study end
Kidney weight (mg/mm tibial length) 14.8 ± 1.4 20.8 ± 2.1* 19.8 ± 3.7* 20.1 ± 2.7* 22.2 ± 2.3*
Food consumption (g/24 h) 5.3 ± 1.1 9.7 ± 2.2* 8.4 ± 2.9* 9.8 ± 1.5* 9.8 ± 3.1*
Water consumption (ml/24 h) 4.1 ± 0.9 21.2 ± 6.3* 19.7 ± 9.3* 23.3 ± 6.5* 24.0 ± 7.5*
Urine output (ml/24 h) 0.4 ± 0.3 15.7 ± 7.8* 13.1 ± 7.1* 16.1 ± 7.6* 17.9 ± 9.6*
Table 1. Baseline and study end anthropometric and biochemical parameters for diabetic (db/db) and non-
diabetic (db/m) mice. Non-diabetic db/m mice (Control); Diabetic db/db mice (Diabetes); Diabetic db/db 
mice + 0.6 mg/kg/day MitoQ orally (DMitoQ); Diabetic db/db mice + 3 mg/kg/day Ramipril orally (DRam); 
Diabetic + 0.6 mg/kg/day MitoQ orally (DMitoQ) + 3 mg/kg/day Ramipril orally (DCoAd); Grey bars/dots 
− diabetic db/db mice + combination of MitoQ and Ramipril (DCoAd). n = 6–13 mice/group. FBG – fasting 
blood glucose; GHb – glycated haemoglobin; KW – kidney weight. Data expressed as Mean ± SEM apart from 
Body wt and KW. *P < 0.05 vs C by 1 W ANOVA/Tukey’s Post-hoc.
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All diabetic mice had renal hypertrophy (Table 1) and mesangial expansion (Fig. 3A; Pictured 3D) by the end 
of the study, irrespective of the therapeutic intervention. Tubulointerstitial collagen IV deposition was ~three-fold 
greater in diabetic versus non-diabetic mice, and this was ameliorated by all therapies (Fig. 3B; Pictured 3E). Mice 
with diabetes also had increased cortical staining of tubulointerstitial collagen using Masson’s Trichrome (Fig. 3C, 
Pictured 3 F), which was also alleviated by each therapy.
Renal cortical energy storage and substrate metabolites. Energy production including concentra-
tions of adenosine based molecules can mediate glomerular filtration33. Diabetes increased the renal cortical 
concentrations of the adenosine based energy storage molecules adenosine tri- (ATP; Fig. 4A) and diphosphate 
(ADP; Fig. 4B) but did not alter the ATP:ADP ratio (ATP:ADP; Fig. 4C). Increases in renal cortical ATP:adenosine 
monophosphate ratio (ATP:AMP; Fig. 4D), AMP (Fig. 4E) and cyclic AMP (ADP; Fig. 4F) concentrations were 
also seen with diabetes. Therapeutic intervention decreased both ATP (Fig. 4A) and ADP (Fig. 4B) concentra-
tions as well as the ATP:AMP ratio (Fig. 4D) in diabetic kidney cortices, but did not affect other adenosine based 
molecules. The renal cortical concentrations of ATP, ADP, cAMP and the ATP:AMP ratio were each signifi-
cantly related to the glomerular filtration rate (GFR; Fig. 4G) but not albuminuria (AER; coefficients not shown). 
Overall there were no significant differences among groups in the ratio of creatine phosphate:ATP (C, 1.2 ± 0.4 vs 
D, 2.5 ± 0.7; P = 0.0 and DMitoQ, 2.3 ± 2.3, DRam, 2.6 ± 1.6, DCoAd, 2.6 ± 1.6).
Central carbon metabolism (CCM) uses a complex series of enzymatic steps to convert nutrients into met-
abolic precursors for energy production within cells. Analyses of renal cortical central carbon metabolites and 
amino acid content were performed (See Supplementary Tables S1–S2 for all metabolites). By applying multivar-
iate analysis (Fig. 5A, OPLS-DA scores plot), the metabolites which best predicted the differences between the 
untreated diabetic group and all other mouse groups were determined. The highest ranked metabolites predicting 
the differences between the db/db diabetic (D) mouse group and all other mouse groups are shown (Fig. 5B). The 
variable importance on prediction (VIP) parameter shown in the table (Fig. 5B) ranks the metabolites in order of 
influence on the multivariate model.
Examination of the specific metabolites ranked by this model showed that the renal cortical concentrations 
of two glycolytic/gluconeogenic metabolites, glucose 6-phosphate (G6P; Fig. 5C, left) and fructose 6-phosphate 
(F6P; Fig. 5C, centre), were increased by diabetes and ameliorated with either monotherapy. There was a positive 
association between renal cortical G6P and F6P concentrations and renal function, defined both by GFR and 24 h 
urinary AER (Fig. 5G). The tricarboxylic acid (TCA) intermediate citrate-isocitrate (Fig. 5C, right) as well as the 
Figure 1. Therapeutical intervention with MitoQ, the ACE inhibitor rampril or their combination, does 
not affect body mass or glucose homeostasis in experimental type 2 diabetes. White bars/circles – Non-
diabetic db/m mice (C); Black bars/circles − diabetic db/db mice (D); Blue bars/circles − diabetic db/db 
mice + 0.6 mg/kg/day MitoQ intragastrically (DMitoQ); Red bars/circles - diabetic db/db mice + 3 mg/kg/
day ramipril intragastrically (DRam); Grey bars/circles - diabetic db/db mice + combination of MitoQ and 
ramipril (DCoAd). Therapies were adminstered for 12 weeks. n = 6–13 mice/group. (A) Fasted plasma glucose 
concentrations; (B) Fasted plasma insulin concentrations; (C) Glycated hemoglobin concentrations; (D) 
Timecourse and (E) AUC plasma glucose concentrations following an intragastric 2 mg/kg D-glucose bolus. (F) 
Body weight. All data are expressed as mean ± SD. *P < 0.05 vs C by 1 W ANOVA/Tukey’s Post-hoc; †P < 0.05 vs 
DMito 1 W ANOVA/Tukey’s Post-hoc; ‡P < 0.05 vs C by Student’s unpaired t-test.
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Figure 2. Once daily administration of MitoQ provides equivalent renoprotection to ACE inhibition in 
experimental diabetes, but combination therapy does not confer superior renoprotection. White bars/squares 
− Non-diabetic db/m mice (C); Black bars/dots - diabetic db/db mice (D); Blue bars/dots − diabetic db/db 
mice + 0.6 mg/kg/day MitoQ intragastrically (DMitoQ); Red bars/dots − diabetic db/db mice + 3 mg/kg/day 
ramipril intragastrically (DRam); Grey bars/dots - diabetic db/db mice + combination of MitoQ and ramipril 
(DCoAd). n = 6–13 mice/group. (A) Twenty four hour urinary albumin excretion rate (AER) early (4 weeks; 
left) and later (9 weeks, right) after treatment commenced. (B) Urinary albumin:creatinine ratio (ACR) at four 
(left) and nine (centre) weeks after treatment commenced. (C) Glomerular filtration rate (GFR) determined by 
transcutaneous decay of FITC-sinistrin dosed by body mass (left) and plasma cystatin C concentration at the 
study end (right). All data are expressed as mean ± SD or median ± interquartile range (cystatin C and ACR) 
when non-parametric. *P < 0.05 vs C by 1 W ANOVA/Tukey’s Post-hoc or Kruskall Wallis/Dunn’s Post hoc; 
†P < 0.05 vs D by 1 W ANOVA/Tukey’s Post-hoc or Kruskall Wallis/Dunn’s Post hoc; ‡P < 0.05 vs D by Student’s 
unpaired t-test.
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electron acceptors, oxidised nicotinamide adenine dinucleotide (NAD+ and NADP+), were also increased in 
diabetic kidney cortices (Fig. 5D). Ramipril decreased the renal oxidised isoforms, NAD+ and NADP+, when 
compared with diabetic mice (Fig. 5D), but MitoQ and combination therapy only trended towards decreasing 
renal NADP+ (P = 0.082) concentrations. Both oxidised NAD+ and reduced NADH were significantly associ-
ated with GFR and AER (Fig. 5G). Renal cortical NADP+ concentrations were related only to GFR and not AER 
(Fig. 5G). Diabetes increased renal concentrations of cytidine monophosphate (CMP; Fig. 5F, left) and decreased 
the amino acid glycine (GLY; Fig. 5F, right) and these were related to AER (Fig. 5G), but were unaffected by ther-
apy (Supplementary Data, Tables S1 and S2).
Differences between MitoQ and Ramipril. A multivariate statistical model including treated and 
untreated diabetic mice was constructed to examine differences between MitoQ and rampril. A representative 
OPLS-DA scores plot of this model is shown (Fig. 6A), highlighting the relative biochemical similarities and 
differences among the groups. The major metabolites predicting the differences between MitoQ and ramipril 
therapy in db/db diabetic mice are shown (Fig. 6B). Diabetes increased the concentrations of dihydroxyacetone 
phosphate (DHAP; Fig. 6C, left), a precursor for glycerol 3-phosphate and synthesis of other fatty acids and 
glucose 1-phosphate (G1P; Fig. 6C, right), a molecule produced during glycogen breakdown by glycogenolysis. 
MitoQ, but not ramipril, therapy attenuated the diabetes-induced increases in renal cortical DHAP and G1P 
(Fig. 6C). The changes in DHAP and G1P were associated with GFR (Fig. 6D) but not urinary AER (coefficients 
Figure 3. MitoQ administration improves tubulointerstitial fibrosis in diabetic (db/db) mice but combination 
therapy is not superior. White bars – Non-diabetic db/m mice (C); Black bars − diabetic db/db mice (D); Blue 
bars − diabetic db/db mice + 0.6 mg/kg/day MitoQ intragastrically (DMitoQ); Red bars − diabetic db/db mice 
+ 3 mg/kg/day ramipril intragastrically (DRam); Grey bars/dots - diabetic db/db mice + combination of MitoQ 
and ramipril (DCoAd). n = 6 mice/group). At the study end, glomerular injury was quantified by (A) Periodic 
Acid Schiff (PAS) staining and assessment of glomerulosclerosis (GSI). Tubulointerstitial injury was assessed by 
(B) Immunohistochemistry for collagen IV (Coll IV). (C) Masson’s Trichrome collagen staining. Representative 
photomicrographs of renal cortical structural markers; (D) PAS (x400); (E) Coll IV (x200) (F) Masson’s 
Trichrome. Scale bar = 20 μm. All data are expressed as mean ± SEM. *P < 0.05 vs C by 1 W ANOVA/Tukey’s 
Post-hoc; †P < 0.05 vs D by 1 W ANOVA/Tukey’s Post-hoc; ‡P < 0.05 vs D by Student’s t test.
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Figure 4. Renal cortical concentrations of adenine based nucleotides relate to glomerular filtration. White 
squares − Non-diabetic db/m mice (C); Black dots - diabetic db/db mice (D); Blue dots − diabetic db/db mice 
+ 0.6 mg/kg/day MitoQ intragastrically (DMitoQ); Red dots − diabetic db/db mice + 3 mg/kg/day ramipril 
intragastrically (DRam); Grey bars/dots - diabetic db/db mice + combination of MitoQ and ramipril (DCoAd). 
n = 6 mice/group. Renal cortical concentrations of (A) adenosine triphosphate (ATP); (B) adenine diphosphate 
(ADP); (C) ATP:ADP ratio; (D) ATP: adenosine monophosphate ratio (ATP:AMP); (E) AMP; (F) cyclic AMP; 
(G) Table of Pearson’s correlation coefficients for associations between renal function (FITC sinistrin based 
GFR) and renal concentrations of adenine molecules. ns – not significant. *P < 0.05 vs C 1 W ANOVA/Tukey’s 
Post-hoc; †P < 0.05 vs D by 1 W ANOVA/Tukey’s Post-hoc; ‡P < 0.05 vs C by Student’s unpaired t test; §P < 0.05 
vs D by Student’s unpaired t test.
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Figure 5. The renal metabolomic profile of central carbon metabolites and amino acids associates with renal 
dysfunction in diabetes. White bars/ squares − Non-diabetic db/m mice (C); Black bars/dots diabetic db/db 
mice (D); Blue bars/triangles − diabetic db/db mice + 0.6 mg/kg/day MitoQ intragastrically (DMitoQ); Red 
bars/squares diabetic db/db mice + 3 mg/kg/day ramipril intragastrically (DRam); Grey bars/dots - diabetic 
db/db mice + combination of MitoQ and ramipril (DCoAd). n = 6 mice/group. (A) Bioinformatic scores plot 
of the OPLS-DA statistical bioinformatic model of all metabolomics data, which demonstrates clear separation 
among mouse groups along the predictive component axis (x axis), with intra-group variability along the 
orthogonal (y axis). (B) Table of the most influential metabolites which define the differences between diabetic 
(D) and all other mouse groups. b-f Renal cortical concentrations of (C) glycolytic/gluconeogenic intermediates 
glucose 6-phosphate (G6P, left), fructose 6-phosphate (F6P) and the TCA cycle intermediates citrate-isocitrate 
(right); (D) oxidised nicotinamide adenine dinucleotides NADP+ (left) and (NAD+, right); (E) the energy 
storage molecules creatinine phosphate (Cre-PO4, left), guanosine diphosphate (GDP, right) and (F) cytidine 
monophsophate (CMP, left); and the amino acid glycine (right). (G) Table of Pearson’s correlation coefficients 
for associations between renal function (GFR and 24 h urinary AER) and the renal cortical metabolites. CCM- 
central carbon metabolite; AAA- amino acid analyte. *P < 0.05 vs C by 1 W ANOVA/Tukey’s Post-hoc; †P < 0.05 
vs D by 1 W ANOVA/Tukey’s Post-hoc; ‡P < 0.05 vs D by Student’s unpaired t test.
www.nature.com/scientificreports/
8SCIeNTIFIC REPORTS | 7: 15190  | DOI:10.1038/s41598-017-15589-x
not shown). The ratio of succinate to fumarate, a surrogate measure of complex II function was increased by dia-
betes and this was attenuated by MitoQ but not ramapril monotherapy (Fig. 6E).
Evidence from in vitro studies suggests that MitoQ may act as an electron carrier by accepting electrons from 
complexes I and II and donating these to complex III, to improve mitochondrial and cellular function34–36. Hence, 
mitochondrial function was examined using a maximal electron flow test measuring oxygen consumption rate 
(OCR) in uncoupled mitochondria during inhibition of various respiratory chain complexes. Here, the flow of 
electrons from complex I to complex IV is monitored in the presence of FCCP, an uncoupler that carries protons 
Figure 6. Differences between MitoQ and rampril treated diabetic kidney cortices. White bars – Non-diabetic 
db/m mice (C); Black bars/dots diabetic db/db mice (D); Blue bars/triangles diabetic db/db mice + 0.6 mg/
kg/day MitoQ intragastrically (DMitoQ); Red bars/squares diabetic db/db mice +3 mg/kg/day ramipril 
intragastrically (DRam); Grey bars/dots - diabetic db/db mice + combination of MitoQ and ramipril (DCoAd). 
n = 6 mice/group. (A) Scores plot of the bioinformatic (OPLS-DA) model including all renal metabolites, 
showing clear separation among diabetic mouse groups where the predictive component 1 axis is for untreated 
diabetic (D) mice vs ramipril treated mice are shown (x axis, PC1), plotted against the predictive component 
2 axis for untreated diabetic mice vs MitoQ treated mice (y axis, PC2). (B) Table of the most influential 
metabolomic variables which define the differences between treated and untreated diabetic mouse groups. 
The variable importance on prediction (VIP) parameter ranks the metabolites in order of significance. Renal 
cortical concentrations of the metabolites which differ between MitoQ and ramipril treated mouse groups, 
(C) dihydroxyacetone phosphate (DHAP) and glucose 1-phosphate (G1P), (D) Pearson’s correlations between 
renal function defined as GFR and G1P/DHAP in all mice. (E) succinate:fumarate ratio, F-h SeaHorse XF24 
Flux Analyses of oxygen consumption rate (OCR) during a maximal electron flow test in isolated uncoupled 
renal cortical mitochondria in the presence of FCCP and the complex I substrates, pyruvate and malate. n = 3 
in the db/m and n = 5 mice/group in the db/db with and without treatment. Line traces of OCR are shown for 
(F) control vs diabetic untreated mice and (G) diabetic MitoQ vs ramipril treated mouse groups - the curve 
for the diabetic untreated group sits below the ramipril group. (H) Mitochondrial OCR responses at baseline, 
following addition of rotenone (CI inhibitor), succinate (CII substrate), antimycin A (CIII) inhibitor and 
ascorbic acid + TMPD − N,N,N′,N′-tetramethyl-p-phenylenediamine (Asc/TMPD; CIV substrates) of the 
mitochondrial respiratory chain. For electron flow, all data are expressed as median ± interquartile range. 
*P < 0.05 vs C; †P < 0.05 vs D; ‡P < 0.05 vs DMitoQ all by 1 W ANOVA/Tukey’s Post-hoc.
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away through the inner membrane without formation of a proton gradient or ATP. Therefore, defects in a specific 
complex can monitor changes in oxygen consumption when a complex-specific substrate is provided. A repre-
sentative trace during the electron flow assay shows that diabetes increased oxygen consumption in renal cortical 
mitochondria when compared with mitochondria from control kidney cortices (Fig. 6F). There were increases 
in oxygen consumption during the electron flow test in diabetic kidney mitochondria following inhibition of 
complex I and addition of the complex II substrate, succinate (Fig. 6F and H). Increased oxygen consumption by 
mitochondria from the diabetic kidney was also seen with inhibition of complex III (Antimycin A) and following 
donation of electrons directly to complex IV (Ascorbate/TMPD). There were no differences in oxygen consump-
tion in uncoupled mitochondria from diabetic versus control kidney cortices at baseline or following complex I 
inhibition (Rotenone, Fig. 6G).
MitoQ monotherapy specifically increased the OCR (Fig. 6F) above that seen in mitochondria taken from 
vehicle treated diabetic mice following inhibition of complex I and addition of the complex II substrate, succinate 
(Fig. 6G). Increases in OCR with MitoQ monotherapy in mitochondria from diabetic mice were also seen with 
inhibition of complex III (Fig. 6G), when compared with mitochondria from untreated diabetic mice (Fig. 6E). In 
the presence of decreased ATP content and unchanged creatine phosphate to ATP ratio, this suggested that MitoQ 
was acting via mitochondrial uncoupling. MitoQ therapy did not influence OCR during the electron flow test at 
baseline, following complex I inhibition nor following donation of electrons to complex IV (Fig. 6F,G). Ramipril 
did not alter oxygen consumption during mitochondrial electron flow testing in diabetic mice (Fig. 6F,G).
Oxidised and reduced coenzyme Q9 and Q10 in the kidney. Since MitoQ is a coenzyme Q deriv-
ative with a lipophilic cation to facilitate trafficking to mitochondria, we assessed whether its mechanism of 
action included effects on mitochondrial concentrations of Coenzyme Q10 (CoQ10). CoQ10 plays a central 
role in trafficking electrons between complexes I, II and III during mitochondrial electron transport. Renal 
concentrations of oxidised (ubiquinone) and reduced (ubiquinol) CoQ9 and CoQ10 were analysed by HPLC 
both in cortical homogenates and isolated mitochondria. At study end, total CoQ9 content in cortical tissue was 
increased in all db/db diabetic mice irrespective of therapeutic intervention (Supplementary Data, Table S3). Total 
CoQ9 to Q10 ratio was also significantly increased by diabetes and not altered by therapy (Supplementary Data, 
Table S3). Cortical and mitochondrial ubiquinol content did not change with diabetes nor therapeutic interven-
tion (Supplementary Data, Table S3).
Discussion
In the present study, we demonstrate that once daily oral administration of MitoQ for 12 weeks improved renal 
function (albuminuria, hyperfiltration) and attenuated tubulointerstitial pathology (collagen) with equivalent 
efficacy to oral ACE inhibition using ramipril. However there were no synergistic benefits seen with their com-
bined administration. The diabetic kidney had elevations in the cortical concentrations of the metabolites of 
oxidative phosphorylation and the purine nucleotides ATP, ADP, cyclic AMP and the ratio of ATP:AMP, as well 
as the phosphate storage molecule and phosphate/ATP buffering molecule, Cre-PO4. All therapeutic interven-
tions attenuated the increases in ATP, ADP and the ATP:AMP ratio. Across all groups, GFR positively corre-
lated with cortical concentrations of the purine nucleotides ATP, ADP, cyclic AMP, the ratio of ATP:AMP and 
Cre-PO4. Interestingly, there was no discernible relationship between albuminuria by AER and the concentra-
tions of these phosphate fuel storage molecules in kidney cortices. Oxidised (NAD+ and NADP+) and reduced 
(NADH) nicotinamide dinucleotide concentrations were elevated by diabetes in renal cortices and related to 
both GFR and AER, irrespective of group. Mechanistically, MitoQ differed from ramipril in that it appeared to act 
as an uncoupler increasing mitochondrial oxygen consumption and limiting ATP production, creating a futile 
cycle where excess energetic flux through the respiratory chain was dissipated as heat. MitoQ also attenuated 
diabetes-induced increases in the glycerol/fatty acid synthesis precursor, DHAP and the breakdown product of 
glycogenolysis, glucose-1-phosphate. The diabetes-induced mesangial matrix expansion was not attenuated with 
either mono- or combination therapy.
Previous studies have identified mitochondrial dysfunction13,17,19,21,27,37, including increases in mitochondrial 
OCR as early pathological events in the kidneys of diabetic rodents11,13. In agreement, we have now shown that 
mitochondria isolated from kidney cortices of diabetic mice have increased OCR and electron flow specifically at 
complexes II through to IV of the electron respiratory chain, most likely due to impairment of complex I activ-
ity, which has been previously shown in the diabetic kidney13,38. In the present study, there were concomitant 
increases in ATP, AMP, and cyclic AMP content as well as elevated ATP:AMP ratios in diabetic kidney cortices9,39. 
Increases in production and/or turnover of renal ATP in our model, agree with a previous study in glomeruli iso-
lated from rodent diabetic kidneys9. However, the higher ratio of creatine phosphate to ATP in our diabetic kid-
ney cortices, indicate that may be the result of a decrease in ATP consumption rather than just over-production, 
suggesting a breakdown in energy sensing feedback loops including via ADP. Indeed, on one hand ADP content 
remained higher in diabetic kidney cortices, which would signal for greater ATP production, increased GFR and 
oxygen delivery. Conversely, however, increases in cellular ATP content could be simultaneously signalling for 
decreased renal ATP production and for decreased GFR in the diabetic kidney stimulating opposing signalling 
pathways. The accumulation of ATP, likely as the result of lower consumption of ATP rather than over production 
by the diabetic kidney, warrants further investigation.
Since mitochondria studied ex vivo from mice treated with MitoQ had greater oxygen consumption in the face 
of decreases in ATP, one could suggest that in vivo during the course of treatment, MitoQ is acting an uncoupler 
of the respiratory chain and ATP production which may be realigning ATP and ADP feedback pathways in the 
kidney, thereby restoring the GFR. Indeed, MitoQ acting in vivo as an uncoupler has been previously described 
in endothelial cells in vitro40. However, these postulates do not explain the elevation in OCR seen with MitoQ. A 
more likely explanation is that MitoQ separated the rate of electron transport in the respiratory chain and oxygen 
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consumption from ATP production, which is supported by the increase in OCR in the face of decreased ATP in 
the present study. Termed as energy dissipating pathways, these processes can increase heat and limit ROS gener-
ation. This could also explain why mitochondria from diabetic mice treated with MitoQ showed increased oxygen 
consumption above that seen in mitochondria from diabetic mice. In addition, these actions of MitoQ in the 
presence of ramipril, where metabolism was already limited, may explain the lack of synergy between these two 
agents in improving renal functional markers in this study. However, this requires examination in future studies.
Activation of pathways by diabetes which require increases in the production and accumulation of renal ATP, 
such as kidney reabsorption of glucose (via sodium dependent glucose transporter, SGLT2), or increases in glyc-
olysis and flux into glucose oxidation could also explain our observed increases in OCR, fuel storage, and cofactor 
molecules as well as renal hyperfiltration41. Previous in vivo studies have shown that increased ATP-dependent 
kidney metabolism/transport, in the context of increased mitochondrial oxygen consumption, is a pathway to 
kidney damage42. In support of this, renoprotection43 is seen following blockade of diabetes-induced increases in 
renal reabsorption of glucose and sodium using SGLT2 inhibitors, which also decrease renal oxygen consump-
tion44,45 and GFR41,46. Lowering of ATP accumulation in the cortical tubules, could also decrease tubuloglomeru-
lar feedback and hence GFR, which is known to be altered by adenine nucleotides. The feedback of high levels of 
both ATP and ADP in the diabetic kidney may be disrupting adenine modulation of tubuloglomerular feedback. 
Interestingly, most of the benefits with therapy in the present study were seen in the tubulointersitium, support-
ing the efficacy of both MitoQ and ramipril in this compartment, by contrast to the lack of effects on glomerular 
fibrosis.
In the current study, MitoQ further elevated mitochondrial OCR at complex II and III during the electron 
flow assay, yet attenuated glomerular hyperfiltration. Although GFR is thought to be tightly coupled to tubular 
oxygen consumption and transport, these data suggest that decreases in renal filtration occurred independently 
of decreases in cortical oxygen consumption44. Another study has also shown a disconnect between oxygen con-
sumption and hyperfiltration in a model of renal damage (Laustsen). Further, as in the present study, increases 
in mitochondrial OCR at complex II and III in conjunction with end-organ protection has been shown with 
MitoQ in previous studies36,47. The specificity of MitoQ effects on OCR at complex II and III is puzzling. MitoQ 
may have altered the activity of complex II (succinate dehydrogenase) in our model, since diabetes elevated renal 
succinate:fumarate ratios. Increases in this ratio, which were ameliorated by MitoQ, suggest a dysfunctional com-
plex II in diabetes. Alternatively, it is also feasible that MitoQ limited the flow of substrates from the Kreb’s cycle 
into OXPHOS since succinate dehydrogenase (complex II) also participates in these reactions. Indeed, this is 
supported by the decreases in ATP and other adenine nucleotides seen with MitoQ.
We observed increases in the glycolytic intermediates G6P, F6P, DHAP and G1P in diabetic kidney cortices, 
which is consistent with a previous study in a model of early kidney disease48. This infers a shift towards glucose 
oxidation including glycolytic pathways in diabetes in order to facilitate cortical demand for ATP production, 
despite maximal energy production via aerobic fuel production (oxidative phosphorylation) from lactate, FFAs 
and glutamine already occurring. This increase in glycolysis in the diabetic kidney may be stimulated by the 
increased accumulation of AMP. This is interesting, given that proximal tubules which constitute a vast propor-
tion of the renal cortex, prefer nutrients other than glucose for ATP generation and have a paucity of rate limiting 
glycolytic enzymes49–53. However, the build-up of G6P and F6P in the diabetic kidney cortex could also reflect 
enhanced gluconeogenesis49,52,53 as well as the activation of glycolysis to meet ATP requirements. Whilst this is 
unresolved in the present study, all therapies decreased G6P and F6P concentrations in the renal cortex, warrant-
ing follow up in future studies.
It is also not clear in the present study why the therapies showed disparate effects on AER and ACR both early 
and later in disease, despite consistent benefits on glomerular filtration. One postulate is that later in this rodent 
model, insulin insufficiency as a result of secretory defects are greater which could have altered lean muscle mass54 
and therefore urinary creatinine excretion. In addition, it is common to use repeated early morning collections 
to estimate ACR and to reach efficacy that is comparable to a 24 hour AER55. Further, albuminuria does fluctuate 
in response to decreases in GFR and can spontaneously regress in some diabetic individuals56. Indeed, this is why 
GFR often provides a more accurate assessment of renal function. Interestingly, GFR rather than albuminuria was 
more strongly correlated with renal cortical changes in ATP and other adenine based molecules in the present 
study. However, albuminuria more strongly related to decreases in other metabolic intermediates assessed in this 
study.
Taken together, these findings suggest that MitoQ confers equivalent renoprotection to a first line therapy for 
DKD, the angiotensin converting enzyme inhibitor, ramipril but their combination does not confer synergistic 
benefits. Derangements in metabolism were prominent in the diabetic kidney with excess production and/or 
less consumption of energetic storage molecules such as ATP, cyclic AMP and Cre-PO4 all strongly correlated 
to glomerular filtration and tubulointerstitial damage. Distinct from ramipril, MitoQ increased mitochondrial 
uncoupling and electron flow at complex II and III during mitochondrial respiration. The action of MitoQ as 
an uncoupler may also explain its lack of synergy with ramipril when they were coadministered. These findings 
should provide the basis for future research to better understand the relationship among delivery of metabolic 
substrates, mitochondrial function and renoprotection in diabetes and a rationale to further examine mitochon-
drial targets as treatments for DKD.
Methods
Experimental Model. All procedures were approved by The University of Queensland Animal Ethics 
Committee in accordance with guidelines from the National Health and Medical Research Council of Australia. 
Male BKS.Cg-Dock7m +/+ Leprdb/J (db/db) mice and heterozygote littermate controls (db/m) were purchased 
from Jackson laboratories (stock number 000642; Bar Harbor, Maine, USA). Mice were housed in an environ-
mentally controlled room (constant temperature 22 °C), with a 12 h light:12 h dark cycle and access to standard 
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chow and filtered tap water ad libitum. At 8 weeks of age, groups (n = 12–13/group) of db/db mice were ran-
domised to daily intragastric gavage of (i) vehicle (D), (ii) mitoquinone (DMitoQ; 0.6 mg/kg, mitoquinone57; 
MS010 a kind gift of Antipodean Pharmaceuticals), (iii) the angiotensin-1 converting enzyme inhibitor (ACE) 
inhibitor, ramipril (DRam; 3 mg/kg/day; kind gift of Sanofi-Aventis Pharmaceuticals) or their combination 
(DCoAd, dosages as per monotherapy) for 12 weeks. A group (n = 11) of non-diabetic db/m littermate control 
mice also received intragastric gavage of vehicle (C) for 12 weeks. Weekly body weight and fasting blood glucose 
(Sensocard glucometer) were monitored throughout the study.
Biochemical Parameters. Early (four weeks) and later (nine weeks) during treatment intervention, mice 
were acclimatised and metabolically caged for 24 h to determine food and water intake and collect urine. Urinary 
albumin and creatinine assays were performed on timed urine collections37. Plasma glucose, insulin and glycated 
hemoglobin were assessed at the beginning and end of the treatment as previously described58. An oral glucose 
tolerance test in response to a 2 mg/kg D-glucose bolus was completed just before the study end at week 11 of 
therapy.
Glomerular filtration rate. Just before the study end, GFR was estimated in conscious mice using the trans-
cutaneous decay of retro-orbitally injected FITC-sinistrin (10 mg/100 g body weight dissolved in 0.9% NaCl), as 
previously described58. Plasma cystatin C was also measured by ELISA at the study end (BioVendor, Brno, Czech 
Republic) according to the manufacturer’s specifications37.
Histology. Paraffin embedded kidney sections were used for the blinded histological assessment of renal 
injury. The degree of mesangial matrix expansion was determined by calculation of glomerulosclerotic index 
(GSI) in twenty glomeruli (x400), using 2 µm kidney sections stained with Periodic Acid Schiff (PAS) as previ-
ously described37. Immunohistochemistry in 4 µm kidney sections with α-collagen IV (1:100 dilution; Abcam, 
Cambridge, USA) was completed using the ABC Elite (Vector Labs, Burlingame, CA)58. Renal cortical collagen 
was determined using Masson’s Trichrome staining58. Percent of positive DAB or Masson’s staining in at least ten 
cortical fields (×100) per mouse were quantified using an Olympus Virtual Slide microscope and NIS Elements 
(Nikon) or Image J (Fiji Distribution Package) software packages.
Metabolomics. Central carbon metabolites and amino acids were analysed by HPLC-MS/MS and 
HPLC-FLD respectively at the study end using triplicate samples from each mouse. Reference standards 
and tributylamine (puriss plus grade) were purchased from Sigma Aldrich (Sigma Aldrich, NSW, Australia). 
LiChroSolv acetonitrile and AR Grade acetic acid were purchased from Merck (Darmstadt, Germany) and 
Labscan (Gliwice, Poland), respectively. Deionised water was generated via an Elga Purelab Classic water puri-
fication unit (Veolia, France). A total of 22 amino acids (and 3 internal standards) were quantified following 
a previously optimized method59. These included Asp, Glu, Cys, Asn, Ser, Gln, His, Gly, Thr, Arg, Ala, GABA 
(4-aminobutyric acid), Tyr, ABU (2-aminobutyric acid), Val, Met, Nva, Trp, Phe, Ile, Orn, Leu, Lys, Sar, Pro. 
Standard Curve from 2–500 μM (double for Pro)
Intermediates of central carbon metabolism (CCM) were analysed following the method described in 
Medina-Torres et al.60 with the following modifications – sample extracts were analysed at two concentrations to 
increase the likelihood of detection for low abundance metabolites as well as to dilute highly abundant metabo-
lites (e.g. AMP, lactate, malate, succinate) into range. Thus, 100 μl of sample extract were dried down in a vacuum 
centrifuge (Eppendorf Concentrator Plus, Eppendorf, Australia) for ~60 min with no heating using the V-AQ 
program. The samples were resuspended in 100 μl of 95:5 water:acetonitrile and 5 μl of this sample removed to a 
fresh vial and then diluted with 195 μl of 95:5 water:acetonitrile to provide an effective forty-fold dilution of the 
original extract. Both sample dilutions were then transferred to HPLC vials for CCM analysis by injection onto 
the HPLC-MS/MS system as described in Medina-Torres et al.60.
Assessment of mitochondrial function. Sequential maximal electron flow through different complexes 
of the mitochondrial electron transport chain was assessed in uncoupled mitochondria using a SeaHorse XF24 
analyser in n = 3 in the db/m and n = 5 mice/group in the db/db with and without treatment. Briefly, 10 µg/well of 
cortical mitochondria per mouse were loaded in triplicate into a 24-well cell culture plate and spun at 2,000 × g 
for 20 min at 4 °C. Mitochondrial oxygen consumption was measured in the presence of complex I substrates glu-
tamate (10 mM) and malate (4 mM) and the uncoupler carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
(FCCP; 4 µM) for 10 min. Sequential injections of rotenone (2 µM, inhibits electron flow at complex I), succinate 
(10 mM, complex II substrate), antimycin A (4 µM (inhibits electron flow at complex III), and ascorbate:N,N,N’,
N’-tetramethyl-p-phenylenediamine (10 mM:100 µM) were used to calculate electron flow at complex I, II, II and 
IV, respectively of the electron transport chain.
Statistical analyses. Kolmogorov-Smirnov and Shapiro-Wilk Tests were applied to the data to assess nor-
mality. Parametric data were analyzed by one-way ANOVA with Tukey’s post hoc correction. For non-parametric 
data, Kruskal-Wallis one-way ANOVA with Dunn’s post hoc correction was performed. Where stated in fig-
ure legends, Student’s unpaired t-test or Mann-Whitney U tests were performed for comparisons between two 
groups. Data are expressed as mean ± SD, unless otherwise stated. P < 0.05 was considered statistically signif-
icant. Metabolomics data were analysed by multivariate analysis methods using SIMCA (MKS Umetrics AB, 
Sweden). Data were initially analysed using Principal Component Analysis (PCA) and subsequently by orthogo-
nal projection to latent structures-discriminant analysis (OPLS-DA) where appropriate.
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